Cephalexin for Oral Suspension USP 250mg/5 mL, Rx Only Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited Mandideep 462 046 India --- NDC 68180-441-01
Published February 6, 2019 · Recall initiated: January 9, 2019
Summary
FDA records drug Class II recall D-0423-2019, published February 6, 2019 and initiated January 9, 2019. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 14,400 bottles; Lot: lot F801282, Expiry June 2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations; presence of extraneous material in the was observed in area that is between the primary package that is heat sealed and secondary packaging (poly-woven bag) of sucrose (an excipient) used in the finished product.
What to do
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get an email if CEPHALEXIN has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- CEPHALEXIN
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Distributor
- Product was distributed to 5 wholesalers, 2 drug chains and 1 supermarket who may have further distributed the product throughout the United States.
- Lot
- lot F801282, Expiry June 2020
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDACephalexin for Oral Suspension, USP, 125 mg per 5 mL, 100 mL (when mixed), Rx Only, Manufactured by: AlkemJune 18, 2025
- FDACephalexin for Oral Suspension, USP, 125 mg per 5 mL, 200 mL (when mixed), Rx Only, Manufactured by: AlkemJune 18, 2025
- FDACephalexin for Oral Suspension, USP, 250mg per 5mL, Rx only, 100mL (when mixed), Each contains cephalexinJune 12, 2024
- FDACephalexin for Oral Suspension, USP, 125mg per 5mL, Rx only, 200mL (when mixed), Each contains: cephalexinJune 12, 2024
- FDABromSite (bromfenac ophthalmic solution) 0.075%, 5 mL bottles, Rx Only, Distributed by : Sun PharmaceuticalFebruary 6, 2019
- FDAFexofenadine HCl Tablets, USP, 180 mg, packaged in a) 30-count bottles (NDC 0378-0782-93) and b) 500-countFebruary 6, 2019
Questions about this recall
Was Cephalexin for Oral Suspension USP 250mg/5 mL, Rx Only Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited Mandideep 462 046 India --- NDC 68180-441-01 recalled?
Yes. FDA published recall D-0423-2019 on February 6, 2019. Reported hazard: CGMP Deviations; presence of extraneous material in the was observed in area that is between the primary package that is heat sealed and secondary packaging (poly-woven bag) of sucrose (an excipient) used in the finished product.
What should I do if I have this product?
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: CEPHALEXIN.